Next Article in Journal
Inhibition of Geranylgeranyl Transferase-I Decreases Cell Viability of HTLV-1-Transformed Cells
Next Article in Special Issue
The Human Antibody Response to Dengue Virus Infection
Previous Article in Journal
Recombination in Avian Gamma-Coronavirus Infectious Bronchitis Virus
Previous Article in Special Issue
Functional RNA Elements in the Dengue Virus Genome
Open AccessReview

Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development

1
Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Room 251, Baltimore, MD 21205, USA
2
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, Room 3W10A, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
Viruses 2011, 3(10), 1800-1814; https://doi.org/10.3390/v3101800
Received: 16 August 2011 / Revised: 20 September 2011 / Accepted: 20 September 2011 / Published: 26 September 2011
(This article belongs to the Special Issue Recent Progress in Dengue Virus Research)
Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.
Keywords: Dengue vaccine; DNA vaccine; vectored-vaccine; sub-unit protein vaccine Dengue vaccine; DNA vaccine; vectored-vaccine; sub-unit protein vaccine
MDPI and ACS Style

Durbin, A.P.; Whitehead, S.S. Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development. Viruses 2011, 3, 1800-1814.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop